Table 3.
Predictors of TB treatment success during the pre- and intra-COVID-19 periods.
| Characteristics | Treatment Success | Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|---|---|
| Yes (N = 617) |
No (N = 591) |
Crude OddsRatio (95% Confidence Interval) | p-Value | Adjusted Odds Ratio (95% Convidence Interval) | p-Value | |
| Gender | ||||||
| Male | 376 (60.9) | 380 (64.3) | 0.87 (0.69–1.10) | 0.228 | 0.78 (0.61–1.00) | 0.053 |
| Female | 241 (39.1) | 211 (35.7) | Reference | Reference | ||
| Age, years | ||||||
| <55 | 565 (91.6) | 510 (86.3) | 1.73 (1.19–2.49) | 0.003 | 1.74 (1.08–2.56) | 0.005 |
| ≥55 | 52 (8.4) | 81 (13.7) | Reference | Reference | ||
| Patient type | ||||||
| Newly diagnosed | 532 (86.2) | 537 (90.9) | 1.59 (1.11–2.28) | 0.012 | 1.69 (1.16–2.47) | 0.007 |
| Relapsed | 85 (13.8) | 54 (9.1) | Reference | Reference | ||
| Type of tuberculosis | ||||||
| Pulmonary | 603 (97.7) | 549 (92.9) | 3.30 (1.78–6.10) | <0.001 | 3.17 (1.67–6.04) | <0.001 |
| Extrapulmonary | 14 (2.3) | 42 (7.1) | Reference | Reference | ||
| Mode of diagnosis | ||||||
| Laboratory-confirmed | 395 (64.0) | 325 (55.0) | 1.46 (1.16–1.83) | 0.001 | 1.14 (0.88–1.47) | 0.318 |
| Clinical diagnosis | 222 (36.0) | 266 (45.0) | Reference | Reference | ||
| HIV status | ||||||
| Positive | 194 (32.1) | 231 (40.4) | Reference | 0.003 | Reference | <0.001 |
| Negative | 411 (67.9) | 341 (59.6) | 1.43 (1.13–1.82) | 1.60 (1.24–2.06) | ||
| Treatment method | ||||||
| Directly Observed Therapy | 404 (65.5) | 445 (75.3) | Reference | <0.001 | Reference | 0.001 |
| Monthly Dispensing for Self-administration | 213 (34.5) | 146 (24.7) | 1.61 (1.25–2.06) | 1.56 (1.21–2.03) | ||